131 related articles for article (PubMed ID: 38805317)
1. New drug approvals for prostate cancer.
Tannock IF
Clin Adv Hematol Oncol; 2024 Jun; 22(5):245-246. PubMed ID: 38805317
[No Abstract] [Full Text] [Related]
2. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
[TBL] [Abstract][Full Text] [Related]
3. Radium - 223 (Xofigo) for prostate cancer.
Med Lett Drugs Ther; 2013 Sep; 55(1426):79-80. PubMed ID: 24081388
[No Abstract] [Full Text] [Related]
4. US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
D'Amico AV
J Clin Oncol; 2014 Feb; 32(4):362-4. PubMed ID: 24344221
[No Abstract] [Full Text] [Related]
5. The androgen receptor, androgen synthesis, and new designer antiandrogens for metastatic castration-resistant prostate cancer: teaching old dogs new tricks.
Lieberman R
Am J Ther; 2013; 20(2):128-31. PubMed ID: 23466618
[No Abstract] [Full Text] [Related]
6. Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond.
Lemery S; Pazdur R
Nat Rev Clin Oncol; 2022 Apr; 19(4):217-218. PubMed ID: 35136230
[TBL] [Abstract][Full Text] [Related]
7. New Indications and Approvals for Anticancer Drugs.
Aschenbrenner DS
Am J Nurs; 2021 Dec; 121(12):16-17. PubMed ID: 34792500
[TBL] [Abstract][Full Text] [Related]
8. Inappropriate use of progression-free survival in cancer drug approvals.
Naci H; Davis C
BMJ; 2020 Mar; 368():m770. PubMed ID: 32156802
[No Abstract] [Full Text] [Related]
9. A new era for castrate resistant prostate cancer: a treatment review and update.
Fong MK; Hare R; Jarkowski A
J Oncol Pharm Pract; 2012 Sep; 18(3):343-54. PubMed ID: 22343966
[TBL] [Abstract][Full Text] [Related]
10. FDA new drug approvals in Q1 2021.
Urquhart L
Nat Rev Drug Discov; 2021 May; 20(5):334. PubMed ID: 33854219
[No Abstract] [Full Text] [Related]
11. Immune-boosting prostate cancer vaccine endorsed by FDA advisors.
McBride D
ONS Connect; 2007 Jul; 22(7):19. PubMed ID: 17694780
[No Abstract] [Full Text] [Related]
12. New prostate cancer drugs hold promise.
Cancer; 2013 Jan; 119(2):247-8. PubMed ID: 23292897
[No Abstract] [Full Text] [Related]
13. 2011 FDA drug approvals.
Mullard A
Nat Rev Drug Discov; 2012 Feb; 11(2):91-4. PubMed ID: 22293555
[No Abstract] [Full Text] [Related]
14. Leuprolide implant approved for once-yearly palliative treatment of advanced prostate cancer.
Oncology (Williston Park); 2000 Jun; 14(6):828, 830. PubMed ID: 10887633
[No Abstract] [Full Text] [Related]
15. Targeting advanced prostate cancer.
Fillon M
J Natl Cancer Inst; 2011 Dec; 103(23):1733. PubMed ID: 22100582
[No Abstract] [Full Text] [Related]
16. Oncology approvals in 2020: a year of firsts in the midst of a pandemic.
Amiri-Kordestani L; Pazdur R
Nat Rev Clin Oncol; 2021 Mar; 18(3):129-130. PubMed ID: 33514911
[TBL] [Abstract][Full Text] [Related]
17. Metastasis-free Survival - A New End Point in Prostate Cancer Trials.
Beaver JA; Kluetz PG; Pazdur R
N Engl J Med; 2018 Jun; 378(26):2458-2460. PubMed ID: 29949489
[No Abstract] [Full Text] [Related]
18. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.
Kim C; Prasad V
JAMA Intern Med; 2015 Dec; 175(12):1992-4. PubMed ID: 26502403
[No Abstract] [Full Text] [Related]
19. The Tradeoff of Cancer Drug Regulatory Policy: Faster Approvals for One Means Less Knowledge for Another.
Tao D; Schott S; Prasad V
Am J Med; 2019 Mar; 132(3):e509-e511. PubMed ID: 30201241
[No Abstract] [Full Text] [Related]
20. Single-arm trials for US Food and Drug Administration cancer drug approvals: Although there are some challenges in using single-arm studies for accelerated drug approvals, it can make a difference in getting drugs previously approved for other uses to patients.: Although there are some challenges in using single-arm studies for accelerated drug approvals, it can make a difference in getting drugs previously approved for other uses to patients.
Nierengarten MB
Cancer; 2023 Jun; 129(11):1626. PubMed ID: 37158643
[No Abstract] [Full Text] [Related]
[Next] [New Search]
